These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 31068088)
21. Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy. Martínez-Marín V; Maki RG Gastroenterol Clin North Am; 2016 Sep; 45(3):477-86. PubMed ID: 27546844 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors. Gupta A; Ma S; Che K; Pobbati AV; Rubin BP PLoS One; 2021; 16(7):e0252689. PubMed ID: 34324512 [TBL] [Abstract][Full Text] [Related]
24. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Komatsu Y; Doi T; Sawaki A; Kanda T; Yamada Y; Kuss I; Demetri GD; Nishida T Int J Clin Oncol; 2015 Oct; 20(5):905-12. PubMed ID: 25655899 [TBL] [Abstract][Full Text] [Related]
25. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib. Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770 [TBL] [Abstract][Full Text] [Related]
26. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313 [TBL] [Abstract][Full Text] [Related]
27. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges. Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553 [TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. Tamoschus D; Draexler K; Chang J; Ngai C; Madin-Warburton M; Pitcher A Clin Drug Investig; 2017 Jun; 37(6):525-533. PubMed ID: 28361439 [TBL] [Abstract][Full Text] [Related]
29. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
30. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib. Lyseng-Williamson KA BioDrugs; 2013 Oct; 27(5):525-31. PubMed ID: 23975637 [TBL] [Abstract][Full Text] [Related]
31. TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors. Khosroyani HM; Klug LR; Heinrich MC Drugs; 2023 Jan; 83(1):55-73. PubMed ID: 36607590 [TBL] [Abstract][Full Text] [Related]
32. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors. Keung EZ; Fairweather M; Raut CP Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287 [TBL] [Abstract][Full Text] [Related]
33. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Schvartsman G; Wagner MJ; Zobniw CM; Trinh VA; Patel S; Somaiah N Curr Oncol Rep; 2016 Aug; 18(8):49. PubMed ID: 27319943 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis. Zhang Z; Jiang T; Wang W; Piao D Medicine (Baltimore); 2017 Dec; 96(48):e8698. PubMed ID: 29310342 [TBL] [Abstract][Full Text] [Related]
35. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848 [TBL] [Abstract][Full Text] [Related]
36. Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review. Abdel-Rahman O; Fouad M Future Oncol; 2015; 11(12):1829-43. PubMed ID: 26075449 [TBL] [Abstract][Full Text] [Related]
37. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Nishida T; Blay JY; Hirota S; Kitagawa Y; Kang YK Gastric Cancer; 2016 Jan; 19(1):3-14. PubMed ID: 26276366 [TBL] [Abstract][Full Text] [Related]
38. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525 [TBL] [Abstract][Full Text] [Related]
39. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours. Shirley M; Keating GM Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375 [TBL] [Abstract][Full Text] [Related]
40. Genetics and treatment of gastrointestinal stromal tumors with immune checkpoint inhibitors: what do we know? Indio V; Astolfi A; Urbini M; Nannini M; Pantaleo MA Pharmacogenomics; 2020 Mar; 21(4):231-234. PubMed ID: 31973655 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]